Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation

Psychiatry Research

Volumn 189, Issue 3, 2011, Pages 463-468

  Matza, Louis S ^a   Phillips, Glenn A ^b   Revicki, Dennis A ^a   Ascher Svanum, Haya ^b   Kaiser, Dawn ^c   Stauffer, Virginia ^b   Shorr, Jodi M ^a   Kinon, Bruce J ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; Discontinuation; Measure development; Patient interview; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; COGNITION; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; INTERVIEW; MALE; MOOD; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT INTERVIEW; PILOT STUDY; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; REASONS FOR ANTIPSYCHOTIC CONTINUATION INTERVIEW; REASONS FOR ANTIPSYCHOTIC CONTINUATION QUESTIONNAIRE; REASONS FOR ANTIPSYCHOTIC DISCONTINUATION INTERVIEW; REASONS FOR ANTIPSYCHOTIC DISCONTINUATION QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SOCIAL SUPPORT; TREATMENT WITHDRAWAL;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; PILOT PROJECTS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 80053457305     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.05.030     Document Type: Article

References (19)

1. Apiquian R., Fresan A., Herrera K., Ulloa R., Loyzaga C., de la Fuente-Sandoval C., Gutierrez D., Nicolini H. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. International Journal of Neuropsychopharmacology 2003, 6(4):403-408.
2. Arato M., O'Connor R., Meltzer H.Y. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology 2002, 17(5):207-215.
3. Binder R.L., McNiel D.E., Sandberg D.A. A naturalistic study of clinical use of risperidone. Psychiatric Services 1998, 49(4):524-526.
4. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medecine 2002, 346(1):16-22.
5. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M. Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999, 20(5):491-505.
6. Davis S.M., Koch G.G., Davis C.E., LaVange L.M. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003, 29(1):73-80.
7. de Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 2002, 162(1):24-28.
8. Dunayevich E., Ascher-Svanum H., Zhao F., Jacobson J.G., Phillips G.A., Delva M.A., Green A.I. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. Journal of Clinical Psychiatry 2007, 68(8):1163-1171.
9. Gitlin M., Nuechterlein K., Subotnik K.L., Ventura J., Mintz J., Fogelson D., Bartzokis G., Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. The American Journal of Psychiatry 2001, 158(11):1835-1842.
10. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983, 13(1):177-183.
11. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet 2008, 371(9618):1085-1097.
12. Karow A., Naber D. Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration. Current Opinion in Psychiatry 2002, 15(1):31-36.
13. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
14. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353(12):1209-1223.
15. Liu-Seifert H., Adams D.H., Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 2005, 3:21.
16. Narendran R., Young C.M., Valenti A.M., Pristach C.A., Pato M.T., Grace J.J. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. Journal of Clinical Psychiatry 2001, 62(7):509-516.
17. Overall J., Gorman D.E. The Brief Psychiatric Rating Scale. Psychological Reports 1962, 10:799-812.
18. Tham J.C., Dickson R.A. Clozapine-induced fevers and 1-year clozapine discontinuation rate. Journal of Clinical Psychiatry 2002, 63(10):880-884.
19. Weiden P., Rapkin B., Mott T., Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz-Lennon M., Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin 1994, 20(2):297-310.